clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Pseudomyxoma Peritonei D011553 1 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Prurigo D011536 4 associated lipids
Proteinuria D011507 30 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Periodontitis D010518 22 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontal Abscess D010508 2 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Peptic Ulcer D010437 19 associated lipids
Parotitis D010309 4 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Parotid Diseases D010305 1 associated lipids
Paronychia D010304 3 associated lipids
Parkinson Disease D010300 53 associated lipids
Pancreatitis D010195 10 associated lipids
Pain D010146 64 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Otitis Media D010033 12 associated lipids
Osteomyelitis D010019 10 associated lipids
Psittacosis D009956 4 associated lipids
Endophthalmitis D009877 12 associated lipids
Nocardia Infections D009617 6 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nasal Polyps D009298 26 associated lipids
Myxoma D009232 1 associated lipids
Myocardial Infarction D009203 21 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Metaplasia D008679 7 associated lipids
Mastoiditis D008417 2 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Mycetoma D008271 4 associated lipids
Lymphangitis D008205 4 associated lipids
Lymphadenitis D008199 8 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Diseases D008171 37 associated lipids
Leprosy D007918 8 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Klebsiella Infections D007710 7 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Ischemia D007511 18 associated lipids
Iritis D007500 2 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kunin M et al. Mycobacterium chelonae peritonitis in peritoneal dialysis. Literature review. 2014 Eur. J. Clin. Microbiol. Infect. Dis. pmid:24569948
Liu KS et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. 2014 Gut pmid:24295850
Miwa S et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. 2014 Ann Am Thorac Soc pmid:24298907
Katayama M et al. Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs. 2014 J. Vet. Med. Sci. pmid:24189617
Papastergiou V et al. Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. 2014 Curr. Pharm. Des. pmid:24180408
Tan X and Song Z Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. 2014 Appl. Biochem. Biotechnol. pmid:24166104
Kakuda TN et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. 2014 J. Antimicrob. Chemother. pmid:24155058
Seung KJ et al. Salvage therapy for multidrug-resistant tuberculosis. 2014 Clin. Microbiol. Infect. pmid:23991934
Yakoob J et al. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori. 2014 Microb. Drug Resist. pmid:23844851
Kathariya R et al. Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial. 2014 J Investig Clin Dent pmid:23097216
Shahbazi Niaz M et al. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. 2014 Pharm Dev Technol pmid:24093825
Maev IV et al. [Eradication therapy for Helicobacter pylori infection: review of world trends]. 2014 Ter. Arkh. pmid:24779078
Katagiri S et al. [Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. 2014 Nippon Naika Gakkai Zasshi pmid:24796145
Kato M [Expanded indication of National Health Insurance for H. pylori associated gastritis]. 2014 Nippon Rinsho pmid:24912302
Bjerre M et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. 2014 Scand. J. Clin. Lab. Invest. pmid:25026506
Khoshnood A et al. Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. 2014 J Med Life pmid:25408735
Noh TK et al. Infection with Mycobacterium fortuitum during acupoint embedding therapy. 2014 J. Am. Acad. Dermatol. pmid:24831334
Fowler J and Mahlen SD Localized cutaneous infections in immunocompetent individuals due to rapidly growing mycobacteria. 2014 Arch. Pathol. Lab. Med. pmid:25076301
Loreto ES et al. New insights into the in vitro susceptibility of Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25223997
Tümgör G et al. Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children. 2014 Turk J Gastroenterol pmid:25910378
Çiftci İH et al. Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of Helicobacter pylori. 2014 Turk J Gastroenterol pmid:25910373
Altman E et al. Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori. 2014 Can. J. Microbiol. pmid:24392924
Kim SY et al. Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease. 2014 Clin. Exp. Immunol. pmid:24354934
De Francesco V et al. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. 2014 J. Med. Microbiol. pmid:24344205
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Lee JY et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. 2014 Dig. Dis. Sci. pmid:24599773
Zhao HM et al. [Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children]. 2014 Zhongguo Dang Dai Er Ke Za Zhi pmid:24661511
Ohe M and Hashino S Successful treatment of primary immune thrombocytopenia in aged patients using clarithromycin. 2014 J. Formos. Med. Assoc. pmid:24630039
Zhou L et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. 2014 Am. J. Gastroenterol. pmid:24642580
Patsche CB et al. Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement. 2014 Int. J. Infect. Dis. pmid:25008771
Koh S et al. Visualization of the meibomian glands by means of noncontact mobile-type meibography (Meibopen) in a 16-year-old girl with unilateral marginal staphylococcal keratitis. 2014 J AAPOS pmid:24568999
Ke AB et al. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. 2014 Clin. Pharmacol. Ther. pmid:24747234
Ghosh N et al. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. 2014 Am. J. Hematol. pmid:24723438
Mendu ML and Waikar SS Drug-drug interactions and acute kidney injury: caveat prescriptor. 2014 Am. J. Kidney Dis. pmid:24820318
Page SR and Yee KC Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. 2014 Intern Med J pmid:25041770
Methaneethorn J et al. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. 2014 Conf Proc IEEE Eng Med Biol Soc pmid:25571290
Hajaghamohammadi A et al. Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial. 2014 Glob J Health Sci pmid:25560342
Iwanczak B et al. Genotypic and clinical differences of seropositive Helicobacter pylori children and adults in the Polish population. 2014 J. Physiol. Pharmacol. pmid:25554984
Rakici H et al. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. 2014 Digestion pmid:25547786
El-Garem Y et al. Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men. 2014 Urology pmid:25432826
Kim SY et al. [Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication]. 2014 Korean J Gastroenterol pmid:25420735
Mustafa G and Necati B Clarithromycin-associated rhabdomyolysis in an infant. 2014 J Clin Rheumatol pmid:25417692
Hashim H et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. 2014 PLoS ONE pmid:25411976
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Martos M et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. 2014 Eur J Gastroenterol Hepatol pmid:25229983
Veraldi S et al. Treatment of sporotrichoid fish tank granuloma with pulsed clarithromycin. 2014 Dermatology (Basel) pmid:25228273
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Klis S et al. Compliance with antimicrobial therapy for buruli ulcer. 2014 Antimicrob. Agents Chemother. pmid:25225342
Mitui M et al. Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. 2014 J. Pediatr. Gastroenterol. Nutr. pmid:25222804
Gold BD Resistance testing for Helicobacter pylori infection: is it finally ready for prime time? 2014 J. Pediatr. Gastroenterol. Nutr. pmid:25222802
Morakul B et al. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. 2014 Eur J Pharm Biopharm pmid:25201298
Parekh TM et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. 2014 JAMA Intern Med pmid:25179404
Kutluk G et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? 2014 Eur J Gastroenterol Hepatol pmid:25171023
Patel SK et al. Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. 2014 Biomed Res Int pmid:25054141
Elkhatib W and Noreddin A Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. 2014 Microb. Drug Resist. pmid:25050970
Ohe M and Bohgaki T Successful treatment with clarithromycin for patients with polymyalgia rheumatica. 2014 Korean J. Intern. Med. pmid:25045305
Martin JH and Coombes I Mortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing. 2014 Intern Med J pmid:25041768
Bansal S and Chhibber S Phytochemical-induced reduction of pulmonary inflammation during Klebsiella pneumoniae lung infection in mice. 2014 J Infect Dev Ctries pmid:25022293
Fouka E et al. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. 2014 Lung pmid:25016929
Lambert D et al. Gastritis due to Helicobacter pylori, an unusual cause of chronic diarrhoea in HIV infected patients. 2014 Med Mal Infect pmid:25015308
Dalbøge CS et al. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. 2014 J. Cyst. Fibros. pmid:24035278
Teh X et al. Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. 2014 PLoS ONE pmid:25003707
Glatz M and Muellegger RR Drug-associated aquagenic wrinkling of the palms in an atopic male patient. 2014 BMJ Case Rep pmid:24903725
DiCicco M et al. In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius. 2014 BMC Microbiol. pmid:24886369
Noonan KA et al. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. 2014 Cancer Immunol Res pmid:24878583
Gong EJ et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? 2014 J. Korean Med. Sci. pmid:24851029
Jeon HK and Kim GH Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea? 2014 J. Korean Med. Sci. pmid:24851014
Rasheed F et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. 2014 Helicobacter pmid:24827414
Wang Y et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. 2014 Helicobacter pmid:24826809
Graham DY et al. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. 2014 Clin. Gastroenterol. Hepatol. pmid:23751282
Pan-In P et al. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. 2014 Carbohydr Polym pmid:24815396
Ichihara A et al. Case of disseminated cutaneous Mycobacterium chelonae infection mimicking cutaneous vasculitis. 2014 J. Dermatol. pmid:24801916
Varvyanskaya A and Lopatin A Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. 2014 Int Forum Allergy Rhinol pmid:24659566
Lee SH et al. Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. 2014 J. Clin. Lab. Anal. pmid:24652818
Binh TT et al. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. 2014 J. Antimicrob. Chemother. pmid:24648504
Tursi A et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. 2014 Panminerva Med pmid:24637473
Wei Z et al. Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients. 2014 Helicobacter pmid:24617669
Wu JY et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. 2014 Helicobacter pmid:24612093
Settin A et al. Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism. 2014 Indian J Gastroenterol pmid:24610583
Garza-González E et al. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. 2014 World J. Gastroenterol. pmid:24587620
Okame M et al. Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy. 2014 Clin. Infect. Dis. pmid:24585569
Mark TM et al. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. 2014 Leuk. Lymphoma pmid:24576165
Zhang J et al. Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. 2014 J Ocul Pharmacol Ther pmid:24199739
Takazono T et al. Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. 2014 BMC Infect. Dis. pmid:24576098
Ali Habib HS et al. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. 2013 Sep-Oct Indian J Pharmacol pmid:24130381
Mégraud F Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. 2013 Nov-Dec Gut Microbes pmid:23929066
Suzaki I et al. Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro. 2013 May-Jun In Vivo pmid:23606690
Dajani AI et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? 2013 May-Jun Saudi J Gastroenterol pmid:23680708
Petitto J et al. Successful clarithromycin desensitization in a macrolide-sensitive pediatric patient. 2013 May-Jun J Allergy Clin Immunol Pract pmid:24565493
Cottle LE et al. A multinational outbreak of histoplasmosis following a biology field trip in the Ugandan rainforest. 2013 Mar-Apr J Travel Med pmid:23464714
Molina-Infante J and Gisbert JP [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. 2013 Jun-Jul Gastroenterol Hepatol pmid:23623461
Razafimahefa SH et al. [Helicobacter pylori: what eradication regimen in a tropical area after the failure of two separate lines of eradication including metronidazole and clarithromycin?]. 2013 Jan-Mar Med Sante Trop pmid:23360589
Mandras N et al. Antibacterial efficacy and drug-induced tooth discolouration of antibiotic combinations for endodontic regenerative procedures. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755774
Morakul B et al. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. 2013 Int J Pharm pmid:24076396
Nykula TD and Furleta VV [Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis]. 2013 Lik. Sprava pmid:25095689
Mikamo H et al. [Infection and host reaction]. 2013 Jpn J Antibiot pmid:24649796
Zhen-Hua Z et al. Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant Helicobacter pylori strains from East China. 2013 Turk J Gastroenterol pmid:23794337
Sarkeshikian SS et al. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. 2013 Turk J Gastroenterol pmid:23794338
Kupcinskas L et al. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. 2013 APMIS pmid:23078193
Liu MK et al. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens. 2013 Kaohsiung J. Med. Sci. pmid:23768702